Wells Fargo & Company Cabaletta Bio, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 13,375 shares of CABA stock, worth $94,828. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,375
Previous 14,058
4.86%
Holding current value
$94,828
Previous $319,000
28.53%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding CABA
# of Institutions
167Shares Held
48.8MCall Options Held
300KPut Options Held
1.31M-
Black Rock Inc. New York, NY4.06MShares$28.8 Million0.0% of portfolio
-
State Street Corp Boston, MA3.74MShares$26.5 Million0.0% of portfolio
-
Jennison Associates LLC3.42MShares$24.3 Million0.04% of portfolio
-
Fred Alger Management, LLC New York, NY3.11MShares$22.1 Million0.27% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.04MShares$21.5 Million0.1% of portfolio
About Cabaletta Bio, Inc.
- Ticker CABA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,014,000
- Market Cap $206M
- Description
- Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...